%0 Journal Article %T PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? %A Addeo, Alfredo %A Banna, Giuseppe Luigi %J Translational Lung Cancer Research %D 2018 %B 2018 %9 %! PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? %K %X We have read with great interest our Colleagues’ point of view suggesting that immunotherapy should not be integrated into the treatment of oncogene-driven non-small cell lung cancers (NSCLCs) based on currently available evidence. However, we would like to mention three points to challenge their recommendation. %U https://tlcr.amegroups.org/article/view/23044 %P S287-S289 %@ 2226-4477